OncRef
Skip to newsletter content
|
NSCLCAugust 2026
0:00 / 3:16
Non-Small Cell Lung Cancer — Monthly Compass
Aug 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in non-small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
non-small cell lung cancer updates
Key Highlights
Key Highlights
  • Important Drug Publication Updates
    • The Lancet Oncology published the global Phase 3 HARMONi primary analysis of ivonescimab plus chemotherapy in EGFR‑mutated NSCLC following progression on a third‑generation EGFR TKI.
  • Key Clinical Development Updates
    • FDA granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic RAS‑mutant NSCLC with KRAS mutations other than G12C and to firmonertinib for first‑line EGFR exon20 insertion‑positive non‑squamous NSCLC, while BH‑30643 received Fast Track status for advanced EGFR C797S‑positive disease after a third‑generation EGFR TKI.
    • FDA accepted the BLA for ivonescimab plus chemotherapy in EGFR‑mutated NSCLC after third‑generation EGFR TKI failure with a PDUFA goal date of November 14, 2026, and Candel opened global enrollment for the pivotal Phase 3 AURORA trial of aglatimagene in metastatic non‑squamous NSCLC progressing after pembrolizumab and platinum chemotherapy.
  • Important Clinical Trial Publications
    • The Phase 3 REZILIENT3 interim analysis demonstrated that zipalertinib plus chemotherapy significantly improved progression‑free survival versus chemotherapy with manageable safety in untreated EGFR exon20 insertion NSCLC.
    • In first‑line NSCLC, the PD‑1/VEGF bispecific ABBV‑1480 combined with chemotherapy achieved objective response rates of 90% in squamous and 75.9% in non‑squamous cohorts with manageable hematologic toxicity.
  • Key Conference Updates
    • August previews for WCLC 2026 highlighted first global novel‑novel IO+ADC data for the PD‑L1×VEGF bispecific pumitamig paired with the B7‑H3 ADC elfetabart drozuntecan and updated perioperative readouts for mRNA immunotherapy BNT116 combined with cemiplimab plus carboplatin/paclitaxel in resectable NSCLC.
  • Emerging Themes & Macro-Trends
    • First‑line NSCLC development is converging on PD‑(L)1×VEGF bispecifics and B7‑H3‑targeted ADC combinations with biomarker‑guided deployment to deepen responses and enable chemo‑sparing backbones.
    • Advancing PD‑(L)1×VEGF bispecific backbones toward Phase 3 are poised to reshape payer frameworks and elevate the importance of companion biomarkers and safety differentiation—particularly hematologic and vascular adverse events—for broad frontline adoption.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-08-01 and 2026-08-31 about non-small cell lung cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Revolution Medicines announced that FDA granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic RAS‑mutant non‑small cell lung cancer (NSCLC) with KRAS mutations other than G12C after prior platinum chemotherapy and anti‑PD‑(L)1 therapy. The company also highlighted continued advancement of its NSCLC program, including the ongoing Phase 3 RASolve 301 trial.¹ (globenewswire.com) (read more)
  • ArriVent BioPharma’s quarterly update reiterated that firmonertinib received FDA Breakthrough Therapy Designation for previously untreated locally advanced or metastatic non‑squamous NSCLC with EGFR exon 20 insertion mutations. The company noted pivotal first‑line NSCLC programs (FURVENT and ALPACCA) advancing toward key 2H 2026 milestones.² (globenewswire.com) (read more)
  • Candel Therapeutics reported that FDA previously granted Fast Track Designation to aglatimagene for NSCLC. The company also opened enrollment and activated the first site for the global pivotal Phase 3 AURORA trial in metastatic non‑squamous NSCLC progressing after pembrolizumab and platinum chemotherapy.³ (globenewswire.com) (read more)
  • BlossomHill Therapeutics received FDA Fast Track Designation for BH‑30643, a macrocyclic OMNI‑EGFR inhibitor, for adults with advanced or metastatic EGFR C797S‑positive NSCLC after a third‑generation EGFR TKI. The program continues in the Phase 1/2 SOLARA trial to support potential expedited development.⁴ (globenewswire.com) (read more)
  • Summit Therapeutics announced publication of HARMONi Phase 3 results and reiterated that FDA accepted the BLA for ivonescimab plus chemotherapy in EGFR‑mutated NSCLC, assigning a PDUFA goal date of November 14, 2026. The filing seeks approval for patients whose disease progressed after a third‑generation EGFR TKI.⁵ (smmttx.com) (read more)
Conference
Major Conference Updates
Conference Information
  • IASLC 2026 World Conference on Lung Cancer (WCLC); Seoul, South Korea; September 12–15, 2026. (read more)
  • August WCLC abstract releases and company previews signal accelerating NSCLC innovation: IO bispecifics and ADCs move into first line, while driver-directed regimens and perioperative immunotherapy expand intent-to-cure strategies. (read more)
  • Theme 1: IO Bispecifics and ADC Combinations Converge in 1L NSCLC
    • Significance: Emergence of dual-pathway immune modulation and cytotoxic delivery promises deeper responses and potential chemo-sparing backbones in frontline disease. (read more)
    • Mechanism insights / clinical impact: PD‑1/VEGF bispecific ABBV‑1480 + chemotherapy showed high ORR (90% squamous; 75.9% non‑squamous) with manageable hematologic toxicity; PD‑L1×VEGF bispecific “pumitamig” paired with B7‑H3 ADC “elfetabart drozuntecan” delivers first-in-lung novel‑novel IO+ADC data, aiming to overcome IO resistance via complementary angiogenesis and T‑cell pathways. (read more)
    • Patient populations affected: First‑line locally advanced/metastatic NSCLC across squamous and non‑squamous histologies; biomarker strategies under evaluation (PD‑L1, VEGF axis; B7‑H3 expression). (read more)
  • Theme 2: Driver‑Directed Intensification in EGFR exon20ins (1L)
    • Significance: Positive interim Phase 3 results for “zipalertinib + chemotherapy” (REZILIENT3) position targeted‑plus‑chemo as a new benchmark for untreated EGFR exon20ins NSCLC and a near‑term registrational catalyst. (read more)
    • Mechanism insights / clinical impact: Zipalertinib (CLN‑081/TAS6417) is an irreversible EGFR inhibitor designed for exon20 insertion variants; REZILIENT3 showed statistically significant, clinically meaningful PFS improvement vs chemotherapy with manageable safety—supporting potential first‑line use. (read more)
    • Patient populations affected: Previously untreated, locally advanced/metastatic non‑squamous NSCLC harboring EGFR exon20 insertions (n≈285 global enrollment). (read more)
  • Theme 3: Perioperative Immunotherapy Expansion with mRNA IO
    • Significance: Neoadjuvant strategies seek to increase pathologic response and long‑term cure rates by priming antitumor immunity pre‑resection. (read more)
    • Mechanism insights / clinical impact: “BNT116” (mRNA cancer immunotherapy) combined with cemiplimab + carboplatin/paclitaxel in resectable NSCLC delivers preliminary clinical readouts, testing synergy between antigen‑specific priming and PD‑1 blockade plus cytotoxic debulking. (read more)
    • Patient populations affected: Resectable early‑stage NSCLC (neoadjuvant setting), with ongoing efforts to define biomarker‑enriched cohorts and perioperative endpoints. (read more)
  • Significance
    • Expected clinical or translational readouts: WCLC oral sessions in Seoul (September 12–15) will detail novel‑novel IO+ADC data (pumitamig/elfetabart drozuntecan) and updated perioperative BNT116 results; REZILIENT3 plenary will disclose Phase 3 efficacy details. (read more)
    • Regulatory or policy implications: REZILIENT3 topline supports planned U.S. submission for zipalertinib + chemotherapy in 1L EGFR exon20ins NSCLC; IO bispecifics (ABBV‑1480) advancing toward Phase 3 could reshape payer frameworks for combination IO in 1L. (read more)
    • Potential shifts in standard of care: Targeted‑plus‑chemo may supersede chemo alone in EGFR exon20ins; IO bispecific backbones could reduce reliance on conventional PD‑1 monotherapy where rapid tumor reduction is needed. (read more)
    • Strategic implications: Investment priority toward PD‑(L)1×VEGF and B7‑H3 ADC ecosystems; companion biomarker development and safety differentiation (hematologic/vascular AEs) will be crucial for broad first‑line adoption and competitive separation. (read more)
Publications Related to Approved Drugs
Phase 3
osimertinib
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. In the pivotal phase III LAURA study, osimertinib demonstrated a manageable and acceptable safety profile for patients with unresectable, stage III EGFR-mutated non-small cell lung cancer following chemoradiotherapy. The data showed that adverse events, including radiation pneumonitis, were generally low-grade and effectively managed, reinforcing osimertinib's position as the new standard of care in this clinical setting. ()
Phase 3
durvalumab
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial. Exploratory analysis of the phase 3 ADRIATIC trial confirmed that consolidation durvalumab provides a consistent and significant survival benefit for patients with limited-stage small-cell lung cancer (SCLC) after concurrent chemoradiotherapy. The benefit was observed across various subgroups, irrespective of the specific chemotherapy regimen, radiation schedule, or use of prophylactic cranial irradiation, solidifying its role as a new standard of care. ()
Phase 3
durvalumab
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. This post-hoc analysis of the PACIFIC trial provides critical strategic insight, revealing that baseline exposure to proton pump inhibitors (PPIs) and antibiotics is associated with reduced progression-free and overall survival in patients with stage III NSCLC treated with durvalumab. These findings suggest that common concomitant medications may attenuate the efficacy of immunotherapy, highlighting a key consideration for patient management and future trial design. ()
Phase 3
ipilimumab
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. A pooled analysis of the CheckMate 227 and CheckMate 9LA studies demonstrates that first-line nivolumab plus ipilimumab, with or without limited chemotherapy, provides long-term, durable clinical benefit in Japanese patients with metastatic NSCLC and low PD-L1 expression (<1%). The combination resulted in a 5-year overall survival rate of 38% versus 16% for chemotherapy, supporting its use as a valuable treatment strategy for this high-unmet-need population. ()
New Publications Related to Drugs in Clinical Trial Development
N/A
Toward uncertainty-aware clinical decision support for treatment response prediction in metastatic NSCLC: integrating FDG-PET, T-cell repertoire, and cytokines with conformal prediction. A novel multimodal biomarker framework that integrates longitudinal FDG-PET, T-cell receptor, and cytokine data demonstrated substantially superior performance over the current PD-L1 tumor proportion score for the early prediction of response to chemoimmunotherapy in metastatic NSCLC. This approach provides an uncertainty-quantified, patient-level prediction that could significantly enhance clinical decision-making and patient selection. ()
Phase 3
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. In a pivotal phase 3 trial for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations, first-line treatment with sunvozertinib resulted in significantly longer median progression-free survival compared to standard chemotherapy (10.3 vs. 7.5 months). These findings establish the superiority of sunvozertinib as a first-line targeted therapy option for this specific molecular subtype of NSCLC. ()
Phase 3
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. For patients with treatment-naive, EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations, the addition of chemotherapy to first-line osimertinib more than doubled the median progression-free survival compared to osimertinib monotherapy (34.0 vs. 15.6 months). This provides a strong clinical rationale for adopting an individualized combination strategy in this high-risk patient population. ()
Phase 2
Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. The irreversible EGFR-TKI sutetinib demonstrated clinically meaningful antitumor activity, achieving a 70.8% objective response rate, in patients with advanced NSCLC harboring uncommon EGFR mutations (G719X, S768I, and L861Q). These results support sutetinib as a potential new standard-of-care treatment option for this molecularly diverse patient population with limited effective therapies. ()
Phase 3
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. The phase 3 E4512 trial concluded that adjuvant crizotinib does not prolong disease-free survival in patients with surgically resected, early-stage ALK-positive NSCLC when compared to observation. These findings do not support the use of crizotinib as an adjuvant therapy in this clinical setting. ()
Phase 2
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. In patients with EGFR-mutated NSCLC that underwent neuroendocrine transformation following progression on first-line osimertinib, treatment with durvalumab plus etoposide-platinum demonstrated a modest objective response rate of 43%. The combination showed a manageable safety profile, suggesting a potential therapeutic strategy for this challenging resistance mechanism. ()
Phase 2
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study. The HYPERBOLIC study is the first prospective, biomarker-driven trial designed to investigate whether adding a short course of platinum-based chemotherapy to first-line cemiplimab can reduce the rate of hyperprogressive disease (HPD) in patients with PD-L1-high NSCLC who are at increased risk. This trial aims to validate a predictive biomarker for HPD and establish a new strategy for early treatment escalation. ()
Phase 3
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. In the LIBRETTO-432 phase 3 trial, adjuvant selpercatinib significantly improved event-free survival compared to placebo for patients with resected stage II or IIIA RET fusion-positive NSCLC. These results establish a new standard of care in the adjuvant setting for this molecularly defined patient population. ()
Phase 3
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. A large phase 3 randomized trial was stopped for futility after finding that adjuvant nivolumab did not improve disease-free survival compared to standard observation in patients with resected NSCLC (without sensitizing EGFR/ALK alterations) who had completed planned adjuvant therapy. This indicates that adjuvant nivolumab is not a beneficial strategy in this post-surgery, post-chemotherapy setting. ()
PHASE1, PHASE2
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. The anti-PD-1/TIGIT bispecific antibody rilvegostomig showed a favorable safety profile and modest antitumor activity in a heavily pretreated, checkpoint inhibitor-experienced population of patients with PD-L1-positive metastatic NSCLC. These encouraging early results support the continued evaluation of rilvegostomig in checkpoint inhibitor-naïve patient cohorts. ()
Phase 2
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9. The combination of enfortumab vedotin and pembrolizumab demonstrated promising clinical activity, with a confirmed objective response rate of 39%, as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma with a PD-L1 CPS ≥1. The regimen's manageable tolerability profile suggests it could become a valuable new therapeutic option for this patient population. ()
Phase 1
T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors. This phase I study confirmed the feasibility and preliminary efficacy of autologous TIL therapy in Asian patients across diverse solid tumors, achieving a 33.3% objective response rate. Furthermore, the study identified ASS1 and CEP20 as novel negative regulators of TIL function, and their knockout via CRISPR/Cas9 enhanced antitumor activity, presenting a promising strategy to improve future TIL-based therapies. ()
Phase 2
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study. In the OCEAN II study, the combination of encorafenib and binimetinib delivered significant clinical benefit to Chinese patients with BRAFV600E-mutated metastatic NSCLC, achieving a confirmed objective response rate of 61% by independent central review. These data confirm the efficacy and safety of this targeted therapy combination within this specific patient population, which has distinct genomic characteristics. ()
Phase 3
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study. After five years of follow-up, the perioperative pembrolizumab regimen in the KEYNOTE-671 study demonstrated durable and clinically meaningful benefits, nearly doubling the 5-year event-free survival rate and showing continued improvement in overall survival for patients with resectable early-stage NSCLC. These long-term results strongly reinforce the use of this regimen as a standard of care. ()
Phase 3
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. A biomarker analysis of the CheckMate 77T study revealed that pre-surgical clearance of circulating tumor DNA (ctDNA) was a top predictor of prolonged event-free survival in patients receiving perioperative nivolumab for resectable NSCLC. These findings offer crucial insights into predictive markers that can help refine patient selection for perioperative immunotherapy. ()
Phase 3
RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC. With an extended follow-up of nearly four years, the RATIONALE-303 study confirmed a sustained and clinically meaningful overall survival benefit for tislelizumab compared to docetaxel in patients with previously treated advanced or metastatic NSCLC. Tislelizumab maintained a favorable safety profile while demonstrating superior long-term efficacy, reinforcing its role as a standard of care in the second-line setting. ()
Phase 3
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer. A unified population pharmacokinetic analysis confirmed that the bevacizumab biosimilar CT-P16 is pharmacokinetically comparable to both EU- and US-sourced reference Avastin® in both healthy subjects and patients with non-squamous NSCLC. This study provides robust evidence supporting the biosimilarity of CT-P16 and highlights how such modeling can streamline biosimilar drug development. ()
Phase 3
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. The SKYSCRAPER-03 study did not meet its primary endpoint, as the addition of the anti-TIGIT antibody tiragolumab to atezolizumab failed to provide additional clinical benefit over the standard-of-care durvalumab as consolidation therapy. This outcome indicates that the tiragolumab-atezolizumab combination is not superior to durvalumab alone in patients with locally advanced, unresectable stage III NSCLC. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in non-small cell lung cancer updated from 2026-08-01 to 2026-08-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting231433126
Recruiting3638515395174
Available-------
Approved for Marketing-------
Active, Not Recruiting161525231190
Completed4-4-3-11
Total58569410767301
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
LOXO-260 NCT05241834 COMPLETED A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors 2026-06-03
Pembrolizumab, AMG 355 NCT06131398 COMPLETED A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors 2026-07-22
Tislelizumab SC, Tislelizumab IV, Histology-Based Chemotherapy Doublet NCT06091943 COMPLETED Phase 1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in the First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer 2026-08-04
Zirconium Zr 89 crefmirlimab berdoxam NCT06863233 COMPLETED Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging 2026-08-24
AB801, Docetaxel NCT06120075 ACTIVE_NOT_RECRUITING A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies 2026-11
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
furmonertinib NCT06812871 COMPLETED A Single-arm, Multicenter, Phase 2 Study of High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis 2026-06-30
concurrent chemotherapy, induction chemo-immunotherapy, Immunotheapy consolidation, Thymosin Alpha1 NCT06139419 COMPLETED A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer 2026-06-30
Tislelizumab NCT05758116 COMPLETED A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients 2026-06-30
Tepotinib, Osimertinib NCT03940703 COMPLETED A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2) 2026-07-15
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
etoposide, carboplatin, cisplatin, : pembrolizumab/vibostolimab, : durvalumab, paclitaxel, pemetrexed NCT05298423 COMPLETED Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC 2026-06-15
: CS1001 monoclonal antibody NCT03789604 COMPLETED A Multi-Center, Randomized, Double-Blind, Phase III Study of Platinum-Containing Chemotherapy With or Without CS1001 in Stage IV Non-Small Cell Lung Cancer Subjects 2026-07-01
Alectinib, Pemetrexed, Cisplatin, Carboplatin NCT06624059 COMPLETED A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status 2026-07-31
JDQ443, docetaxel NCT05132075 ACTIVE_NOT_RECRUITING A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer 2026-09-23
MRTX849, Docetaxel NCT04685135 ACTIVE_NOT_RECRUITING A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation 2026-10-30
Savolitinib, Cisplatin, Carboplatin, Osimertinib, Pemetrexed NCT05261399 ACTIVE_NOT_RECRUITING A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON). 2026-11-23
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.